

GLAXOSMITHKLINE PLC  
Form 6-K  
February 25, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc (GSK) was advised on 25 February 2016 of the following increases in the notional allocation of GSK American Depositary Shares (ADSs) on 23 February 2016, at a price of \$38.64 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401(K) plan:

| Director/PDMR | Number of ADSs |
|---------------|----------------|
|---------------|----------------|

|               |    |
|---------------|----|
| Dr M M Slaoui | 51 |
|---------------|----|

| Connected Person | Number of ADSs |
|------------------|----------------|
|------------------|----------------|

|  |   |
|--|---|
| Dr K Slaoui (Connected<br>Person of Dr M M Slaoui) | 4 |
|--|---|

V A Whyte  
Company Secretary

25 February 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: 25 February, 2016

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc